Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 322-329

  Pischon, Tobias ^a   Hu, Frank B ^b,c   Girman, Cynthia J ^d   Rifai, Nader ^e,f   Manson, JoAnn E ^b,c   Rexrode, Kathryn M ^c   Rimm, Eric B ^b,c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adiponectin; Cohort study; Coronary disease; Epidemiology; Risk factors

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FATALITY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MOLECULAR WEIGHT; PROSPECTIVE STUDIES; RISK;

EID: 80055012490     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.011     Document Type: Article

References (32)

1. Pischon T. Adiponectin: a biomarker of obesity?. Curr Cardiovasc Risk Rep 2008, 2:150-155.
2. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
3. Schulze M.B., Shai I., Rimm E.B., et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539.
4. Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007, 92:571-576.
5. Lindsay R.S., Resnick H.E., Zhu J., et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005, 25:e15-e16.
6. Lawlor D.A., Davey Smith G., Ebrahim S., Thompson C., Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677-5683.
7. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629.
8. Koenig W., Khuseyinova N., Baumert J., Meisinger C., Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 2006, 48:1369-1377.
9. Soderberg S., Stegmayr B., Stenlund H., et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004, 256:128-136.
10. Matsumoto M., Ishikawa S., Kajii E. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke 2008, 39:323-328.
11. Ingelsson E., Riserus U., Berne C., et al. Adiponectin and risk of congestive heart failure. JAMA 2006, 295:1772-1774.
12. Whitehead J.P., Richards A.A., Hickman I.J., Macdonald G.A., Prins J.B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264-280.
13. Heidemann C., Sun Q., van Dam R.M., et al. Total high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008, 149:307-316.
14. Sattar N., Watt P., Cherry L., et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J Clin Endocrinol Metab 2008, 93:1846-1849.
15. Colditz G.A., Manson J.E., Hankinson S.E. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997, 6:49-62.
16. Willett W. Nutritional epidemiology 1998, Oxford University Press, New York.
17. Prentice R.L., Breslow N.E. Retrospective studies and failure time models. Biometrika 1978, 65:153-158.
18. Pischon T., Hotamisligil G.S., Rimm E.B., Adiponectin Stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003, 49:650-652.
19. Rothman K.J., Greenland S. Case-control studies. Modern epidemiology 1998, 93-114. Lippincott-Raven, Philadelphia. K.J. Rothman, S. Greenland (Eds.).
20. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
21. Szmitko P.E., Teoh H., Stewart D.J., Verma S. Adiponectin and cardiovascular disease: state of the art?. Am J Physiol Heart Circ Physiol 2007, 292:H1655-H1663.
22. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753.
23. Kuller L.H., Grandits G., Cohen J.D., Neaton J.D., Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2006.
24. Karakas M., Zierer A., Herder C., et al. Leptin adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis 2010, 209:220-225.
25. Quatromoni J., Jones R. Inequalities in socio-economic status and invasive procedures for coronary heart disease: a comparison between the USA and the UK. Int J Clin Pract 2008, 62:1910-1919.
26. Laughlin G.A., Barrett-Connor E., May S., Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007, 165:164-174.
27. Wang Z.V., Scherer P.E. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008, 51:8-14.
28. Matsuura F., Oku H., Koseki M., et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007, 358:1091-1095.
29. Oku H., Matsuura F., Koseki M., et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007, 581:5029-5033.
30. Tsubakio-Yamamoto K., Matsuura F., Koseki M., et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008, 375:390-394.
31. Tian L., Luo N., Klein R.L., et al. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009, 202:152-161.
32. Rathmann W., Herder C. Adiponectin and cardiovascular mortality: evidence for " reverse epidemiology" Horm Metab Res 2007, 39:1-2.